News Releases
- Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 August 5, 2020
- Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil August 5, 2020
- Algernon Highlights UT Dallas Research Study Identifying Ifenprodil as a Possible COVID-19 Treatment July 21, 2020
- Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19 July 16, 2020
- Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia July 7, 2020
- Algernon Pharmaceuticals Announces Extension of Exercise Date of Warrants July 7, 2020
- Algernon Receives Ethics Approval for U.S. Sites for 2b/3 Human Study of Ifenprodil for COVID-19 June 25, 2020
- Algernon Pharmaceuticals Announces Deemed Exercise of Special Warrants June 12, 2020
- Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19 June 4, 2020
- Algernon Pharmaceuticals Discusses Multinational Phase 2b/3 Ifenprodil COVID-19 Human Trial on BioPub Webcast Hosted by Dr. KSS MD PhD May 28, 2020